What is HC Wainwright’s Forecast for SNDX FY2024 Earnings?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – HC Wainwright increased their FY2024 EPS estimates for shares of Syndax Pharmaceuticals in a report issued on Wednesday, November 6th. HC Wainwright analyst E. White now anticipates that the company will earn ($3.83) per share for the year, up from their previous forecast of ($3.94). HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.66) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q4 2024 earnings at ($1.20) EPS, FY2025 earnings at ($3.75) EPS and FY2026 earnings at ($2.96) EPS.

A number of other brokerages also recently issued reports on SNDX. UBS Group initiated coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They set a “buy” rating and a $37.00 price target on the stock. JPMorgan Chase & Co. lowered their price target on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Stifel Nicolaus increased their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Citigroup increased their price target on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, StockNews.com raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $35.82.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ SNDX opened at $21.52 on Friday. The company’s fifty day moving average price is $19.09 and its 200 day moving average price is $20.33. Syndax Pharmaceuticals has a 1 year low of $13.14 and a 1 year high of $25.34. The company has a market capitalization of $1.83 billion, a PE ratio of -6.37 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.16 million. During the same period last year, the company earned ($0.73) earnings per share.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. acquired a new stake in Syndax Pharmaceuticals during the second quarter worth about $27,000. Values First Advisors Inc. acquired a new stake in Syndax Pharmaceuticals during the third quarter worth about $30,000. nVerses Capital LLC acquired a new stake in Syndax Pharmaceuticals during the second quarter worth about $33,000. Mirae Asset Global Investments Co. Ltd. increased its position in Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the last quarter. Finally, Quarry LP increased its position in Syndax Pharmaceuticals by 75.0% during the second quarter. Quarry LP now owns 6,125 shares of the company’s stock worth $126,000 after purchasing an additional 2,625 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).